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AbstrACt
Introduction Gout is increasing despite effective 
therapies to lower serum urate concentrations to 
0.36 mmol/L or less, which, if sustained, significantly 
reduces acute attacks of gout. Adherence to urate-
lowering therapy (ULT) is poor, with rates of less than 
50% 1 year after initiation of ULT. Attempts to increase 
adherence in gout patients have been disappointing. We 
aim to evaluate the effectiveness of use of a personal, self-
management, ‘smartphone’ application (app) to achieve 
target serum urate concentrations in people with gout. We 
hypothesise that personalised feedback of serum urate 
concentrations will improve adherence to ULT.
Methods and analysis Primary care. A prospective, 
cluster randomised (by general practitioner (GP) practices), 
controlled trial.
Participants GP practices will be randomised to either 
intervention or control clusters with their patients allocated 
to the same cluster.
Intervention The intervention group will have access to 
the  Healthy. me app tailored for the self-management of 
gout. The control group patients will have access to the 
same app modified to remove all functions except the Gout 
Attack Diary.
Primary and secondary outcomes The proportion 
of patients whose serum urate concentrations are less 
than or equal to 0.36 mmol/L after 6 months. Secondary 
outcomes will be proportions of patients achieving target 
urate concentrations at 12 months, ULT adherence rates, 
serum urate concentrations at 6 and 12 months, rates of 
attacks of gout, quality of life estimations and process and 
economic evaluations. The study is designed to detect a 
≥30% improvement in the intervention group above the 
expected 50% achievement of target serum urate at 6 
months in the control group: power 0.80, significance level 
0.05, assumed ‘dropout’ rate 20%.
Ethics and dissemination This study has been approved 
by the University of New South Wales Human Research 
Ethics Committee. Study findings will be disseminated in 
international conferences and peer-reviewed journal.
trial registration number ACTRN12616000455460.
bACkground
Gout is increasingly prevalent and its inci-
dence is rising. It afflicts 7% of men in the 
UK over 65 years and is the most common 
inflammatory arthritis in men, affecting 
1%–2% in Western countries.1–5 Australian 
research indicates that gout is a significant 
and an increasing problem, with at least 1.5% 
of the general population affected.6 Further 
complicating management, there is a high 
incidence of comorbidities recognised in 
gout patients especially insulin resistance 
and diabetes, heart failure, hypertension and 
chronic kidney disease.4 7 
Gout is a chronic disease triggered by the 
crystallisation of urate within joints, leading 
to inflammation, painful flares and eventual 
joint damage and destruction.5 8 Individuals 
who suffer acute attacks of gout recurrently 
endure debilitating pain, disruption of their 
life and significant costs.9–14 Gout results 
from excessive accumulation of urate due 
to a combination of genetic and lifestyle 
factors with the latter including diet, alcohol 
strengths and limitations of this study
 ► The study tests an app designed with input from 
people with gout to enhance adherence to urate-
lowering therapy.
 ► The intervention delivers personalised feedback on 
achievement of target serum urate concentration.
 ► Serum urate concentration is a very good surrogate 
for the likelihood of future gout attacks.
 ► Not all people use apps.
 ► A large number of participants need to be recruited 
to provide sufficient power to demonstrate a relevant 
effect size.
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and smoking habits.5 15 Recent evidence indicates that 
elevated urate is an independent risk factor for accel-
erated cardiovascular and renal disease.16–19 However, 
if urate concentrations in the blood are reduced to 
≤0.36 mmol/L, attacks of gout can be eliminated and the 
risks of kidney disease and possibly premature cardiovas-
cular disease reduced.20 Existing urate-lowering therapies 
(ULT) are relatively safe and effective in reaching these 
target serum urate concentrations. The predominately 
prescribed ULT is allopurinol which works via inhibiting 
the synthesis of urate. Probenecid is an alternate ULT 
that enhances the renal clearance of urate, however, this 
is rarely used. More recently available is febuxostat that 
also inhibits the formation of urate.21
Poor adherence to long-term ULT is likely to be the 
most important contributor to the suboptimal outcomes 
experienced by patients with gout.22 Medication non-ad-
herence is substantial in patients with gout, with studies 
consistently reporting that less than half of patients are 
adherent with treatment.23–26 Recent research suggests 
that non-adherence may be worse in gout than in any 
other chronic disease.27 Many reasons for non-adherence 
have been identified including limited knowledge about 
the causes and consequences of gout, lack of under-
standing about the different therapeutic approaches, 
uncertainty about therapeutic options to take if an attack 
occurs, insufficient appreciation of the importance of 
adherence to ULT, confusion regarding contributions of 
diet and lifestyle to gout and stigma associated with the 
diagnosis.23 25 26 28 In many patients with recurrent gout 
attacks, the adherence standard required is demanding, 
as ULT needs to be taken every day to avoid a recurrence. 
An important factor that impinges on adherence during 
the early months of therapy is a paradoxical increase in 
the risk of acute attacks even though serum urate concen-
trations are falling. The natural reaction of patients is 
to stop the therapy if not forewarned. Not surprisingly, 
patients can quickly lose confidence in their ULT.23 
Fortunately, the risk of acute attacks can be significantly 
lowered during ULT initiation by taking an additional 
medicine as prophylaxis against acute attacks, such as 
regular, low-dose colchicine or non-steroidal anti-in-
flammatory drug.29 Additionally, it is likely but not yet 
finally established, that commencing ULT with a low dose 
and increasing the dose at 2–3 week intervals will lower 
the risk of a hypersensitivity reaction to allopurinol but 
also the risk of an acute attack.5 30 The key message for 
patients and their doctors is to continue taking ULT every 
day during this period even if an attack occurs.
There is accumulating evidence to suggest that elec-
tronic aids including mobile phone applications (apps) 
can improve adherence to preventative and therapeutic 
interventions including medications and lifestyle prac-
tices in chronic conditions such as diabetes, hypertension, 
mental illness and also arthritis.31 32 Apps are an increas-
ingly accessible option via smartphones and tablets. 
There is also the potential to incorporate personalised 
feedback against targets such as adherence to medicines 
into apps. An attractive option for patients with gout is 
to provide feedback regarding their urate concentrations 
and whether target concentrations have been achieved, 
given the close correlation between these values and the 
risk of attacks of gout.20  Healthy. me is an app for patients 
developed to improve their health outcomes through 
better self-management. Research using this app has 
shown that personally held information improved health 
decision-making, uptake of therapy and organisation of 
health-related tasks.33 34 Users also valued social interac-
tions and peer support provided by this app. Yet there are 
too few rigorous, controlled investigations of the effec-
tiveness of such consumer electronic health (eHealth) 
applications.35 36 Also, the few apps available for self-man-
agement for patients with gout had multiple limitations 
and had not been tested in patients for effectiveness.35 
Gout, with its high prevalence and impact despite the 
availability of proven effective therapy is a good target for 
enhancing patient self-management with a purpose built 
app. This study aims to test the effectiveness and cost-ef-
fectiveness of an app to enhance self-management in gout 
patients in primary care.
AIM
The aim of this study is to evaluate whether the use of an 
app that provides personal feedback and alerts to patients 
with gout to take their medication (intervention app) in 
addition to standard care, will significantly increase the 
proportion of patients reaching a target serum urate 
≤0.36 mmol/L at 6 months compared with those using 
a control app with limited features (gout attacks diary 
only), which is close to standard care. The duration of 
the study will be 12 months.
MEthods
study design and recruitment procedures
This 1-year study is a prospective, clustered by primary 
care practice, randomised, controlled trial. The recruit-
ment of general practitioner (GP) practices and patients 
with gout from the practices is presented in figure 1. 
GPs will be recruited from a list of practices in Sydney 
and rural centres in New South Wales Australia using GP 
networks, e-mail, direct mail, newsletters and telephone 
to advertise the study to GPs. Specifically, primary health-
care networks (PHNs) that are federally funded and in 
NSW are geographically aligned with the 15 hospital 
networks will be approached to publicise the study. PHNs 
work with primary healthcare providers including GPs to 
increase efficiency and effectiveness of medical services 
and improve coordination of care with the hospital 
networks.
Inclusion criteria for GPs to participate in the study 
will be that they use electronic patient records and 
prescribing systems and have seen patients with gout in 
the past year. Once a GP has consented to participate, 
their practice will be randomised, using a pre-prepared, 
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randomisation sequence and designated as ‘intervention’ 
or ‘control’ practice. Any patient enrolled via that prac-
tice would be similarly designated. All GPs in that practice 
will be approached to participate. Each participating GP 
will be asked to identify more people with gout. Patient 
inclusion and exclusion criteria are presented in table 1.
Patients with a diagnosis of gout by their GP, either new 
or a flare-up of previously diagnosed gout, who have expe-
rienced at least two attacks of acute gout in the previous 
year will be invited by their GP to participate in this study. 
Patients may already be taking ULT or be a candidate for 
restarting or commencing ULT (table 1).
Additional patients with possible or proven gout may 
also be identified via community pharmacies, emergency 
departments, specialist rheumatologists or consumer 
groups for example, Arthritis Australia, who are aware 
of the study. If these patients are willing to be consid-
ered for study entry they will be asked to contact the 
study personnel who will prescreen them via phone for 
potential suitability for inclusion. If apparently eligible, 
the study personnel will ask the patient’s GP if they are 
also willing to consent to participate in the study and 
identify patients with gout to be invited to the study. 
Once the consent is obtained, the participating GP will 
be randomised to either an intervention or control prac-
tice and requested to recruit patients for the study. The 
apparently eligible patient and subsequently recruited 
patients (if any) will be allocated into the same inter-
vention or control group as the participating GP. The 
patients will be screened against inclusion and exclusion 
criteria and formally invited by their GP to consent to 
participate.
Figure 1 Patient recruitment and study timeline. ED, Emergency Department; GP, general practitioner.
Table 1 Patient inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Adults (>18 years)
 ► Diagnosis of gout by GP (either new or flare up) and have experienced 
at least two attacks of acute gout in the previous year
 ► Receiving ULT treatment or candidate to start or restart ULT treatment
 ► Access to a smartphone device and the internet
 ► Sufficient English language to complete questionnaires
 ► Give consent for access to their PBS and MBS data files
 ► Lack of technological experience so that 
participation in the study would be difficult—
determined during screening via interview
 ► Psychological condition (ie, cognitive deficiency) 
that may impede participation in the study
MBS, Medical Benefits Scheme; PBS, Pharmaceutical Benefits Scheme; ULT, urate-lowering therapy.
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After giving informed consent, patients in the inter-
vention and control groups will be commenced on or 
continue ULT and will be treated as is customary by their 
GPs. We expect to begin enrolment of participants in 
October 2017.
randomisation
GP practices will be randomised by an independent 
researcher to either intervention or control group with 
a 1:1 allocation using random block size of 2 or 4 and 
computer-generated randomisation sequence. After the 
study personnel have obtained consent from patients 
recruited from the participating GP practices, the inde-
pendent researcher will send the patients an e-mail 
containing a link to install either the intervention app or 
the control app on their smartphone or tablet. Neither 
GPs from the participating practices nor the participating 
patients will be informed of whether the patients are in 
the intervention group or control group although each 
patient can see what their app contains and each GP will 
receive a description of contents of the app provided to 
their patients. Two researchers, who will independently 
conduct data analyses, will be blinded to group allocation 
to minimise bias.
gout-specific ehealth self-management app ( healthy. me gout)
The intervention group will be provided with access to 
the  Healthy. me app tailored for the self-management of 
gout.  Healthy. me is a self-management eHealth app avail-
able on smartphones and tablets that contains features 
to help patients manage their chronic diseases. It has 
been designed and validated in a two-group, parallel, 
randomised controlled trial as effective in increasing 
consumers’ vaccination rates.33 34 The app has been 
tailored to promote effective self-management of gout 
and long-term adherence to ULT. The app was devel-
oped, using dimensions of the Health Belief Model: 
perceived susceptibility, perceived severity, perceived 
benefits and perceived barriers.34 In addition, input 
provided by patients with gout in focus group discussions 
informed the development of the app.36 While education 
materials from the app raise awareness of consequences 
of uncontrolled gout, susceptibility to gout attacks when 
serum urate concentrations are high, and the importance 
of keeping a low-serum urate level, the key feature of the 
app, ‘Uric Acid Tracker’, is designed to provide person-
alised feedback on susceptibility to and severity of gout 
by presenting individual patients’ serum urate levels and 
gout attack data on a graph. This personalised feedback 
will enable the patients to relate their high-serum urate 
levels to the occurrence of gout attacks (perceived suscep-
tibility and severity) and recognise attack-free benefits 
of ULT adherence behaviour when their serum urate is 
consistently low. Low medication adherence is a major 
barrier to keeping gout under control,23 and thus the app 
is designed to include educational content and pop-up 
alerts to remind the patients to take their ULTs. Specifi-
cally, the intervention app contains these features:
Uric acid tracker
Serum urate results will be recorded and graphed under 
the ‘uric acid tracker’ function. Patients will be asked to 
obtain their serum urate results from their GP or pathol-
ogist after every test and promptly enter the results into 
this feature of the app. Alerts within the app will be trig-
gered if serum urate is not in the target range, recom-
mending that patients discuss their gout management 
with their GP. The patient’s serum urate concentrations 
will be represented in a graph over time and in relation-
ship to the target serum urate (≤0.36 mmol/L) (figure 2).
Gout facts
Educational materials including written information 
and a video animation about gout and its management 
for people with gout will be available via the app. The 
following topics are covered: what is gout, why take ULT 
medication, the effects of ULT, what to do in a gout attack 
and the importance of ULT adherence.
Electronic gout attacks diary
This feature provides the ability to record gout attacks 
including pain intensity, location of attack(s) or joint(s) 
affected and triggers. The gout attack data that patients 
enter will be presented in the graph next to serum urate 
levels.
Schedule
This feature can be used as an alternative to the calendar 
function of smart devices if patients prefer to use it for 
management of their gout. Patients can schedule their 
tasks, such as having blood tests and collecting results, 
seeing their GP or other members of their care team and 
recording gout attacks.
Team
Contact details of GP, pathology service, researchers and 
others such as rheumatologist, physiotherapist and so on 
can be listed.
Diet tips
An evidence-based list of foods that can raise or lower 
serum urate will be available.
baseline data collection
Patients will be asked to complete demographic (including 
age, sex, marital status, ethnicity, socioeconomic status, 
level of education), quality of life, workplace productivity 
and medication adherence questionnaires. They will also 
provide details of their medical history—of gout (onset, 
frequency of attacks, treatments), ULT and dose, alcohol 
history, other medications (especially diuretics and low 
dose aspirin) and comorbidities (cardiovascular, renal, 
endocrine, etc). These data will be collected via electronic 
tablets provided by the researchers, paper forms or via the 
study internet site. Researchers will be available to assist 
patients at all stages of this process either face to face, via 
the internet or by phone. Electronic or online question-
naires will be the preferred method for collection of this 
 5Day RO, et al. BMJ Open 2017;7:e017281. doi:10.1136/bmjopen-2017-017281
Open Access
information to minimise non-complete or incomplete 
response as the respondent can be reminded if all ques-
tions have not been answered. Completing questionnaires 
provides an opportunity for any questions from the patient 
to be answered by researchers. Data from GP records (see 
below) will be accessed to complete and cross-check rele-
vant details of the patient’s medical histories.
Intervention group
Patients in the intervention group will be provided with their 
personal login details to access and download the  Healthy. 
me gout management app and installation guide. They will 
have access to a short introduction to the ‘ Healthy. me app’ 
and its features via an e-mail or in paper form. There will be 
an opportunity for patients to ask researchers any questions 
via the website, e-mail, phone or face to face. Patients will 
have access to the app for 12 months. Patients’ GPs will also 
have access to the introductory material about the app and 
the content of educational materials in the app.
Control group
The control group patients will be provided with their 
personal login details to access and download the  Healthy. 
me modified gout app and installation guide. The full 
version of the Healthy.Me app tailored for patients with 
gout will be modified to remove all functions except the 
gout attack diary, which contains fields to record only the 
date of attack, pain intensity and location of attack but not 
triggers. Thus, the control group patients can neither enter 
their serum urate data into the app nor view the graph. 
They will be provided with this control app to collect gout 
attack data as an important secondary outcome measure of 
this study. They will be informed that the study is tracking 
their gout experience over the year following entering the 
study. They will be asked to return to their GP for assess-
ment and serum urate and ULT concentrations at 6 and 12 
months independent of other visits they may make to their 
GP. Reminders to visit their GP and have blood tests will 
only occur via short message service (SMS) and/or e-mail 
immediately prior to 6 and 12-month visits to optimise their 
retention in the study.
gP role
GPs will be asked for access to eligible and consenting 
patients’ (both intervention and control) medical records 
at baseline, 6 and 12 months. Details about each patient’s 
medical history of gout (onset, frequency of attacks, 
treatments), ULT dose, alcohol history, other medica-
tions (especially diuretics and low-dose aspirin), comor-
bidities (cardiovascular, renal, endocrine) and medical 
examination details (weight, height, blood pressure) will 
be extracted from the medical record by the researchers 
to complement and cross-check the data collected from 
participants. GPs will also provide patients’ blood (serum 
urate, creatinine and oxypurinol or febuxostat) test 
results throughout the study or approve copies being sent 
to the research team direct from the pathology service.
Pathology service role
One to 2 weeks prior to scheduled or recommended 
follow-up appointments, reminders will be sent to 
patients via SMS and/or e-mail to have a blood test for 
serum urate, creatinine and oxypurinol (the active form 
of allopurinol) or febuxostat concentrations at their GP 
Figure 2 ‘Urate tracker’ personalised for each 'intervention' participant. ULT, urate-lowering therapy.
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or pathology service. Researchers will then collect these 
results via letter or fax from the GP, practice staff or from 
the pathology service, confirm via the patient’s  Healthy. 
me account the accuracy of the serum urate data that 
patients entered in the ‘intervention’ app and record 
other blood test data in the study’s database (for assess-
ment purposes). Depending on which ULT a patient 
is prescribed, either oxypurinol or febuxostat concen-
trations will be forwarded from pathology services to 
the Clinical Pharmacology Department at St Vincent’s 
Hospital for measurement, as this laboratory has vali-
dated assays for these drugs. Assays for probenecid are 
not available for this study.
data collection during the study
Intervention and control participants will be asked to 
attend their GP clinic at 0, 6 and 12 months (see table 2). 
Participants will be asked to complete the same question-
naires at each of these visits using a tablet provided, paper 
forms or the internet. Additional visits to GPs, serum 
urate and creatinine concentrations and gout attacks 
will be recorded. These data will be sourced from apps, 
GP records, Medicare data (which will include details of 
healthcare consultations) and pathology services for each 
study participant. These overlapping sources of informa-
tion will be used to verify the accuracy of data collected. 
At the 6 and 12 months visits, participants will have the 
opportunity to discuss their progress, adverse events or 
questions or concerns they may have with researchers and 
their GPs. Participating patients will be reimbursed for 
their time with a AUD$30 gift voucher after completing 
both a blood test and the survey at each time point of the 
study: the start, 6 months and 12 months. Assuming that 
they complete the study in its entirety, they will receive a 
total of three $30 gift vouchers ($90).
Primary outcome
Serum urate concentration
Patients in both control and intervention groups will 
attend their GP and/or pathology clinic at 6 months to 
have their serum urate concentration measured. Consis-
tency between laboratories will be ascertained according 
to quality control protocols established by the National 
Association of Testing Authorities, Australia.37 The 
proportion of patients in the intervention and control 
groups whose plasma urate is less than or equal to the 
target urate of 0.36 mmol/L will be compared.
secondary outcomes
Serum urate concentrations
All urate concentrations, along with creatinine concen-
trations performed in the 1 year of the study, will be 
collected. An expectation is that the intervention group 
will have more urate tests performed especially in the first 
6 months of the study. The 12-month urate concentration 
measurement will indicate whether achievement of target 
concentrations at 6 months is sustained. The number of 
serum urate concentration tests undertaken over 6 and 
12 months in each group will be compared. Change in 
serum urate concentrations from baseline to 6 and 12 
months will be evaluated also.
Adherence
Along with serum urate concentrations, serum oxypu-
rinol or febuxostat concentrations will be measured in 
patients at the same time they have their blood collected 
and tested at their GP or pathology service. Oxypurinol, 
the active metabolite of allopurinol, or febuxostat concen-
trations will give an indication of a patient’s adherence to 
ULT.
In addition to serum oxypurinol and febuxostat concen-
trations, patients will complete a validated Medication 
Adherence Scale.38 This will be completed at baseline, 6 
months and 1 year and focused on ULT.
Gout attacks
The occurrence and intensity of gout attacks will be 
self-reported by intervention and control participants 
via the ‘gout attacks diary’ on the app as attacks occur. 
Patients will be able to enter the date and duration of 
their attack, as well as rate the intensity of the pain using 
a rating scale from 1 to 10.
Impact of gout and health-related quality of life
Impact of gout on health-related quality of life will be 
measured using the gout impact section of the Gout 
Assessment Questionnaire V.2.0,39 which contains ques-
tions on well-being during gout attacks, gout medica-
tion side effects, unmet gout treatment needs and gout 
concerns overall and during attacks. Utility scores derived 
from the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) 
will also be used in a secondary analysis.40 Both instru-
ments will be administered at baseline, 6 and 12 months.
Work productivity
Work productivity impairments and impairment in daily 
activities will be assessed at baseline, 6 and 12 months 
using the validated ‘Work Productivity and Activity 
Impairment’ (WPAI) questionnaire.41 This information 
will be used in the cost-effectiveness analysis.
statistical considerations
Sample size calculation
An intracluster (practice) correlation coefficient of 0.01 
for the primary outcome, within the range for similar 
cluster randomised studies in Australian and interna-
tional general practices, was used for power calcula-
tions.42–44 The primary outcome is the achievement of 
the target serum urate concentration, that is, less than or 
equal to 0.36 mmol/L at 6 months. This serum concen-
tration outcome, if maintained, is a very strong predictor 
that gout attacks will no longer occur. Rates of achieve-
ment of target urate in gout patients, with approximately 
the same inclusion criteria and offered standard treat-
ment, lie anywhere between 28% and 69%.45 Based on 
these studies, we have assumed that 50% of the standard 
care group will achieve the target urate concentration at 
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6 months. We expect that this is an optimistic prediction. 
Although there are few studies published on effect sizes 
achieved for interventions centred on eHealth tools, this 
study will attempt to demonstrate that 65% of participants 
in the intervention group will achieve the target, that is, a 
relative increase of 30% compared with the 50% of partic-
ipants expected to achieve the target in the control group 
at 6 months (an absolute increase of 15%). The investiga-
tors believe that this effect size will be significant clinically 
and also at a population level. To demonstrate an effect of 
this size with 80% power and statistical significance level 
for a two-sided test of 5%, we will need 186 patients in each 
study arm to complete the study. To accommodate a 20% 
drop-out rate of participants at 6 months, and assuming 
no GP practices drop-out but accounting for the effect of 
the cluster design,46 558 patients will be recruited in total. 
A target of at least 3 patients per practice will mean 186 
practices would need to be recruited.
Data will be analysed using SAS V.9.4. Missing-at-
random data will be handled using multiple imputation. 
The intention-to-treat principle will be applied and the 
significance level will be set at 0.05. Intracluster (practice) 
correlation coefficients will be determined. The primary 
outcome at 6 months of the control and intervention 
groups will be compared using the method of general esti-
mating equations, and also for each outcome, to account 
for the correlation within practices. The effects on adher-
ence will be explored and correlations with primary and 
secondary outcomes sought.
Baseline comparisons of demographic variables will be 
performed using independent samples t-tests. Random 
effects mixed modelling will be used with baseline, 6 and 
12 months and group allocation (intervention, control) 
as the fixed factors. Sociodemographic factors will be 
controlled for in the analysis. If the proportion of partic-
ipant’s baseline serum urate less than 0.36 mmol/L is 
greater than 20%, stratification will be performed.
Economic and process evaluations
An economic evaluation will be conducted to understand 
the potential investment case of the intervention for the 
Australian health system. First, the within trial cost-ef-
fectiveness of the intervention compared with usual 
care plus control app will be estimated in terms of the 
incremental cost per (1) patient achieving the primary 
outcome and (2) quality adjusted life year gained using 
the utility scores derived from the EQ-5D-5L, given 
the previous use of EQ-5D in economic evaluations of 
ULT.40 Costs will be derived from all aspects of the inter-
vention (eg, software implementation and maintenance, 
training) as determined from project files and direct 
medical costs (eg, GP visits, medications, pathology 
tests, hospitalisations) as determined from GP records 
and valued at prevailing rates. In addition, indirect 
(productivity) costs incurred (or avoided) by patients 
will be collected by participant self-report using the 
WPAI questionnaire that will be administered at base-
line, 6 and 12 months.41 These costs will be included as 
a sensitivity analysis to estimate the impact of these costs 
on cost-effectiveness estimates.
Second, to understand the cost-effectiveness of the 
Healthy. me gout app beyond the trial, a Markov model 
will be used to track a group of surviving patients at 
the end of the trial over time in which they potentially 
progress through a number of health states including 
serum urate concentrations controlled, uncontrolled and 
death.47 48 49 The transition probabilities across various 
defined health states, costs and quality of life attached to 
various health states will be based on published evidence. 
Using appropriate discounting, estimates of long-term 
costs and outcomes will emerge from the model and an 
incremental cost-effectiveness ratio estimated. A series 
of sensitivity analyses will be conducted including on 
discount rates, uncertainty in outcome estimates and 
variations in costs that may occur across different settings 
so as to explore important questions about the potential 
scalability and generalisability of this intervention.
A process evaluation will also be undertaken using qual-
itative research methods to understand how and why the 
intervention was (or was not) working in practice. At the 
completion of the study, a random sample of patients 
and GPs will be interviewed employing a semistructured 
interview. Interview questions will be open ended and 
will be developed to appreciate participants’ views on the 
app and its value to them.50 Interviews will be audiore-
corded and transcribed verbatim. A general inductive 
approach will be used for analysis. Two researchers will 
independently analyse transcripts and meet periodically 
throughout data collection to discuss emerging themes, 
resolve any discrepancies and determine when theme 
saturation occurs and thus no further interviews are 
needed. Back-end data from the app, which give informa-
tion on the app usage, will also be included in the anal-
ysis. These data will be considered secondary outcomes 
of the study.
data management
Data will be managed using Microsoft Office Excel and 
stored in password-protected files. To ensure that each 
patient and participating GP’s personal identifiers and 
relevant data sets are deidentified, each participant will 
be allocated an identification number instead of a name 
for analysis. Analysis of the transcripts from the focus 
groups/interviews and patient medical data will occur 
only after the transcripts and medical data are deidenti-
fied by the researcher who undertook the data collection, 
hence protecting the personal details of the participants. 
The number allocated to a participant will be recorded 
in a separate file from the data. This ensures that their 
confidentiality is maintained throughout the study. The 
chief investigators and statisticians in the research team 
will have access to the final trial dataset.
dissemination
Throughout the duration of the study, clinical data will 
be available to the patients if they wish. At the conclusion 
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of the study, participants will be given a written report of 
the study's findings. The results will also be disseminated 
via publication in journals and presentations in scientific 
meetings by the investigators. Additionally, partners in 
this project may also release general information of find-
ings on their associated websites and media releases.
Ethical approval
This study has received ethical approval from the 
University of New South Wales Human Research Ethics 
Committee and is registered with the Australian New 
Zealand Clinical Trials Registry (Trial Registration: 
ACTRN12616000455460, Date registered: 7 April 2016). 
Any important modification to the protocol, made in this 
version (dated 8 August 2017), will need to be approved 
by the project steering committee and be submitted to 
the ethics committee and the trial registry through appro-
priate channels before the trial begins.
The protocol conforms to the SPIRIT statement 
(2013)51 and study results will be presented according to 
the CONSORT statement for cluster, randomised clinical 
trials.52
dIsCussIon
Improved gout management offers benefits at both an 
individual and societal level. Adherence with long-term 
treatment can alleviate gout flares and the associated 
decreased quality of life, disability and long-term sequelae 
due to the chronic inflammation of gout. At a societal 
level, improved management of gout can significantly 
reduce the substantial economic burden associated with 
uncontrolled gout.53 There are little available data on 
the Australian-specific burden of disease due to gout, but 
because of similar health demographics, the USA is often 
accepted as having a comparable health outcome profile 
to Australia. Total annual direct medical costs related to 
gout in the USA have been estimated to be about $4 billion 
and total annual indirect costs at $2.6 billion.54 It has been 
shown that gout patients with poorly controlled serum 
urate concentrations incur on average higher healthcare 
costs than patients whose serum urate concentrations are 
better controlled.55 56 In light of this, cost-effective means 
of maintaining ULT adherence, and thereby reducing 
the prevalence of gout, is likely to be highly valuable.
Poor adherence, failure of initiation and under dosing 
of ULT all contribute to the unacceptably high preva-
lence of uncontrolled gout. The hypothesis for this study 
is that effective education for patients with gout about 
how to manage their condition combined with person-
alised feedback regarding serum urate concentrations 
will significantly enhance adherence to ULT, thereby 
reducing the incidence of acute gout attacks. This study 
will be the first comprehensive examination of the effec-
tiveness of an eHealth tool designed to help patients 
self-manage their chronic gout. The process involved in 
establishing and undertaking this proposed intervention 
will also be evaluated along with an economic evaluation 
of the intervention. Cluster, randomised, controlled trials 
are ideally suited to test interventions where individual 
patient randomisation is not possible.57 These types of 
studies commonly use a parallel group design, in which 
the clusters are randomised to either the intervention 
or control arm of the study. It is expected that the real 
world, primary care setting of the study and identifica-
tion and recruitment of patients from additional sources, 
including other health services and community-based 
sources, will optimise the generalisability of study find-
ings. In addition, the study findings will be relevant to 
promoting adherence to therapy in people with other 
chronic illnesses.
Behaviour change needed to improve adherence 
to medications and other therapeutic interventions 
for chronic health conditions is notoriously difficult 
to accomplish.58–60 Attempts to improve adherence to 
ULT in individuals with gout have also been generally 
unsuccessful or marginally effective and difficult to 
sustain. There are particular additional impediments 
to improved adherence in patients with gout. For most 
chronic conditions such as hypertension, adequate 
adherence to medications that should be taken regu-
larly, usually daily, is deemed to be about 80% although 
the evidence supporting this level of adherence is diffi-
cult to find.61 This level of adherence for a patient with 
recurrent attacks of gout however, is unlikely to be satis-
factory. These patients are prone to attacks during the 
periods of both stopping and starting ULT and 1 or 
2 days missed therapy is enough to precipitate an attack 
in many gout sufferers. To reduce the risk of attacks 
during the establishment of ULT, it is recommended 
that doses are escalated over weeks and prophylactic 
comedications such as colchicine are given.29 Even with 
these measures that are complex for patients to under-
stand, there is still the risk of an acute attack and the 
sufferer needs to know that ULT should not be stopped. 
Therefore, it is not surprising that adherence to the 
level required is not often achieved and that the inter-
ventions to-date have been disappointing.
Personalised feedback is a proven method of changing 
behaviour.60 Sustained reduction of urate concentra-
tions to 0.36 mmol/L or below is a very well established 
surrogate indicator for elimination of recurrent attacks 
of gout.62 The use of electronic tools especially apps to 
provide personalised feedback on urate concentrations 
and high-quality education and alerts may be an effec-
tive approach to positively impacting adherence to ULT.
Focus group discussions with patients with gout 
during the app development phase indicated their 
strong beliefs that certain foods and beverages precipi-
tated their attacks and their desire to be able to record 
this information in their gout attack diaries. Thus, ‘Diet 
Tips’ feature with dietary information is provided in the 
app. While there is insufficient evidence on the clinical 
effectiveness of dietary intervention alone in lowering 
urate levels in gout patients, we cannot exclude the 
evidence on associations between certain foods and risk 
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of gout, for example, higher levels of meat and seafood 
consumption and an increased risk of gout.63 In addi-
tion, the existing guidelines on gout management 
recommend patient education on diet and lifestyle.64
It is possible that the control app containing the ‘gout 
attacks diary’ feature only may have some effect on 
self-management of the control group although it does 
not actively provide personalised feedback. One alterna-
tive to obtain the gout attack data (a secondary outcome 
measure) was to provide paper diaries to the control 
group to record acute attacks, whereas the intervention 
group would be able to record their attacks on the app. 
Another option was to ask the control group to recall 
acute attacks and their intensity at the 6 and 12-month 
assessments. Neither would escape a reporting bias 
favouring the apparent efficacy of the control app. If 
power and resources were not a constraint, a third study 
arm with no app could have been included. Providing 
the control group with the app (containing this limited 
feature) may also reduce the risk of selective withdrawal 
of participants in this group and poor response in the 
follow-up assessments due to disappointment for being 
in the control group and not receiving an app.65
Customary management of gout in primary care can 
be suboptimal. This study is testing the effectiveness of 
the app in the existing primary care context, and the 
design of the intervention does not include educating 
GPs in best practice. With the trust that randomis-
ation works, the suboptimal gout management will 
be balanced between intervention group and control 
group, and the study will be testing the effectiveness of 
the app only. There is an expectation that patients with 
the test app could ‘reverse’ educate their GPs to some 
extent, and this would contribute to the effectiveness of 
the intervention.
The results from this prospective, cluster randomised 
controlled trial will provide important insights into the 
effectiveness of an app designed to promote enhanced 
self-management of gout. Information about the 
reactions of patients to the features of the app and 
the rates of use of these features will also be valuable 
when considering potential modifications to the app. 
It will also provide data for the cost-effective analysis. 
On a larger scale, results from this study will deliver 
significant evidence-based guidance for future clinical 
eHealth initiatives relevant to chronic disease.
This protocol has been reviewed and endorsed 
by The Australia and New Zealand Musculoskeletal 
(ANZMUSC) Clinical Trials Network (http:// anzmusc. 
org/).
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